ClinicaliQ Trial Snapshot
- Multicentre Hypertrophic Cardiomyopathy Registry — Recruiting • Cardiology / Cardiovascular • NCT07381894.
- What is being tested: A multicentre registry collecting comprehensive clinical data on hypertrophic cardiomyopathy patients to understand disease progression, phenotypes, and outcomes across diverse UK populations, rather than testing a specific intervention.
- Patient eligibility overview: Individuals with diagnosed or suspected hypertrophic cardiomyopathy are enrolled, including those with obstructive disease (LVOT obstruction causing symptomatic blockage) and non-obstructive variants, capturing the full spectrum of HCM presentations.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart condition, affecting approximately 1 in 500 people. It causes the heart muscle to thicken, which can lead to blockages in blood flow (left ventricular outflow tract obstruction), shortness of breath, and an increased risk of heart failure or sudden cardiac arrest. While standard treatments exist and new targeted medications (cardiac myosin inhibitors) have recently been approved, doctors still need better data to predict which treatments will work best for each individual patient. This national registry based in the UK is a…
Eligibility Snapshot
- : * Confirmed diagnosis of Hypertrophic Cardiomyopathy (HCM) clinically and not solely explained by abnormal loading conditions (e.g., significant hypertension, valvular disease
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.